PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.79%
Both companies show declining cash positions (-9.79% vs GNPX's -4.83%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Cash + STI yoy ≥ 1.5x GNPX's -4.83%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.77%
≥ 1.5x GNPX's -5.99%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-10.21%
1.25-1.5x GNPX's -8.53%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.10%
Below half of GNPX's 8.32%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
≥ 1.5x GNPX's -5.65%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
3.20%
Less than half of GNPX's 76.64%. David Dodd sees a more disciplined AP approach or lower volume.
-75.32%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-4.13%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
0.52%
Less than half of GNPX's 56.66%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.45%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.62%
Less than half of GNPX's 56.66%. David Dodd sees far fewer liability expansions relative to competitor.
7.69%
Above 1.5x GNPX's 2.16%. Michael Burry suspects heavy new equity expansion or dilution.
-2.53%
Below half GNPX's -5.50%. Michael Burry suspects major net losses or high dividends vs. competitor.
-4.62%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
≥ 1.5x GNPX's -6.26%. David Dodd sees stronger capital base growth than competitor.
-9.71%
≥ 1.5x GNPX's -5.65%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-19.69%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
9.58%
Above 1.5x GNPX's 4.83%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.